<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">33968470</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">2163-0402</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>11</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neurology. Clinical practice</Title>
          <ISOAbbreviation>Neurol Clin Pract</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inpatient vs Outpatient Evaluation of Suspected Paraneoplastic Cerebellar Degeneration.</ArticleTitle>
        <Pagination>
          <StartPage>33</StartPage>
          <EndPage>42</EndPage>
          <MedlinePgn>33-42</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1212/CPJ.0000000000000854</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the differences in outcomes of adult patients with ataxia initially evaluated for paraneoplastic cerebellar degeneration (PCD) as inpatients or outpatients.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In this retrospective cohort analysis, diagnosis, workup, and functional outcomes based on the change in the modified Rankin Scale (mRS) score were compared between patients with ataxia who underwent workup for PCD initially as inpatients vs outpatients between March 2011 and June 2018 at Rush University Medical Center.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 78 patients included in the analysis; 59% were women, and the average age at symptom onset was 57 ± 19.5 years. Nineteen patients (24.3%) underwent evaluation as inpatients and 59 (75.6%) as outpatients. Admitted patients were more likely to receive immunotherapy (73.7% vs 20.3%, <i>p</i> &lt; 0.0001) and received it faster than outpatients (0.40 months for inpatients, interquartile range [IQR] 0.03-1 months, vs 6.6 months for outpatients, IQR 2-11.7 months; <i>p</i> = 0.01). A greater percentage of inpatients improved based on the mRS score compared with those who underwent evaluation as outpatients (52.63% vs 22.81%, <i>p</i> = 0.01).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">More patients improved from baseline in the inpatient cohort.</AbstractText>
          <AbstractText Label="CLASSIFICATION OF EVIDENCE" NlmCategory="METHODS">This study provides Class III evidence that for patients undergoing initial evaluation for PCD, patients undergoing inpatient evaluation have better outcomes compared with those undergoing outpatient evaluation.</AbstractText>
          <CopyrightInformation>© 2020 American Academy of Neurology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Witek</LastName>
            <ForeName>Natalie</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Movement Disorders (NW, MA, DH), Rush University Medical Center, and Biostatistical Analysis (YL, BO), Department of Neurological Sciences, Rush University Medical Center, Chicago, IL.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Afshari</LastName>
            <ForeName>Mitra</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Movement Disorders (NW, MA, DH), Rush University Medical Center, and Biostatistical Analysis (YL, BO), Department of Neurological Sciences, Rush University Medical Center, Chicago, IL.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yuanqing</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Movement Disorders (NW, MA, DH), Rush University Medical Center, and Biostatistical Analysis (YL, BO), Department of Neurological Sciences, Rush University Medical Center, Chicago, IL.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ouyang</LastName>
            <ForeName>Bichun</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Movement Disorders (NW, MA, DH), Rush University Medical Center, and Biostatistical Analysis (YL, BO), Department of Neurological Sciences, Rush University Medical Center, Chicago, IL.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hall</LastName>
            <ForeName>Deborah</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Movement Disorders (NW, MA, DH), Rush University Medical Center, and Biostatistical Analysis (YL, BO), Department of Neurological Sciences, Rush University Medical Center, Chicago, IL.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neurol Clin Pract</MedlineTA>
        <NlmUniqueID>101577149</NlmUniqueID>
        <ISSNLinking>2163-0402</ISSNLinking>
      </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>25</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33968470</ArticleId>
        <ArticleId IdType="pmc">PMC8101295</ArticleId>
        <ArticleId IdType="doi">10.1212/CPJ.0000000000000854</ArticleId>
        <ArticleId IdType="pii">NEURCLINPRACT2019046052</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clinic Proc
2010;85:838–854.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2931619</ArticleId>
            <ArticleId IdType="pubmed">20810794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojas I, Graus F, Keime-Guibert F, et al. . Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology
2000;55:713–715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10980743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol
2008;7:327–340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2367117</ArticleId>
            <ArticleId IdType="pubmed">18339348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitoma H, Manto M, Hampe CS. Immune-mediated cerebellar ataxias: from bench to bedside. Cerebellum Ataxias
2017;4:16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5609024</ArticleId>
            <ArticleId IdType="pubmed">28944066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitoma H, Manto M, Hampe CS. Time Is Cerebellum. London: Cerebellum; 2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6028834</ArticleId>
            <ArticleId IdType="pubmed">29460203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nanri K, Okuma M, Sato S, et al. . Prevalence of autoantibodies and the efficacy of immunotherapy for autoimmune cerebellar ataxia. Intern Med
2016;55:449–454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26935362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones AL, Flanagan EP, Pittock SJ, et al. . Responses to and outcomes of treatment of autoimmune cerebellar ataxia in adults. JAMA Neurology
2015;72:1304–1312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26414229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurol
2002;1:294–305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12849427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blaes F, Strittmatter M, Merkelbach S, et al. . Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders. J Neurology
1999;246:299–303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10367699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Delattre JY, Antoine JC, et al. . Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry
2004;75:1135–1140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1739186</ArticleId>
            <ArticleId IdType="pubmed">15258215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zesiewicz TA, Wilmot G, Kuo SH, et al. . Comprehensive systematic review summary: treatment of cerebellar motor dysfunction and ataxia: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology
2018;90:464–471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5863491</ArticleId>
            <ArticleId IdType="pubmed">29440566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perlman S. Evaluation and Management of Ataxic Disorders: An Overview for Physicians. Minneapolis, MN: National Ataxia Foundation; 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>Samii A, Ryan-Dykes P, Tsukuda RA, Zink C, Franks R, Nichol WP. Telemedicine for delivery of health care in Parkinson's disease. J Telemed Telecare
2006;12:16–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16438773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keime-Guibert F, Graus F, Fleury A, et al. . Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry
2000;68:479–482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1736897</ArticleId>
            <ArticleId IdType="pubmed">10727484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saif MW, Tzannou I, Makrilia N, Syrigos K. Role and cost effectiveness of PET/CT in management of patients with cancer. Yale J Biol Med
2010;83:53–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2892773</ArticleId>
            <ArticleId IdType="pubmed">20589185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ebright MJ, Li SH, Reynolds E, et al. . Unintended consequences of Mayo paraneoplastic evaluations. Neurology
2018;91:e2057–e2066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6282240</ArticleId>
            <ArticleId IdType="pubmed">30366974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganesh A, Wesley SF. Practice current: when do you suspect autoimmune encephalitis and what is the role of antibody testing?
Neurol Clin Pract
2018;8:67–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5839684</ArticleId>
            <ArticleId IdType="pubmed">29517071</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">33968470</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">2163-0402</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>11</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neurology. Clinical practice</Title>
          <ISOAbbreviation>Neurol Clin Pract</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inpatient vs Outpatient Evaluation of Suspected Paraneoplastic Cerebellar Degeneration.</ArticleTitle>
        <Pagination>
          <StartPage>33</StartPage>
          <EndPage>42</EndPage>
          <MedlinePgn>33-42</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1212/CPJ.0000000000000854</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the differences in outcomes of adult patients with ataxia initially evaluated for paraneoplastic cerebellar degeneration (PCD) as inpatients or outpatients.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In this retrospective cohort analysis, diagnosis, workup, and functional outcomes based on the change in the modified Rankin Scale (mRS) score were compared between patients with ataxia who underwent workup for PCD initially as inpatients vs outpatients between March 2011 and June 2018 at Rush University Medical Center.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 78 patients included in the analysis; 59% were women, and the average age at symptom onset was 57 ± 19.5 years. Nineteen patients (24.3%) underwent evaluation as inpatients and 59 (75.6%) as outpatients. Admitted patients were more likely to receive immunotherapy (73.7% vs 20.3%, <i>p</i> &lt; 0.0001) and received it faster than outpatients (0.40 months for inpatients, interquartile range [IQR] 0.03-1 months, vs 6.6 months for outpatients, IQR 2-11.7 months; <i>p</i> = 0.01). A greater percentage of inpatients improved based on the mRS score compared with those who underwent evaluation as outpatients (52.63% vs 22.81%, <i>p</i> = 0.01).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">More patients improved from baseline in the inpatient cohort.</AbstractText>
          <AbstractText Label="CLASSIFICATION OF EVIDENCE" NlmCategory="METHODS">This study provides Class III evidence that for patients undergoing initial evaluation for PCD, patients undergoing inpatient evaluation have better outcomes compared with those undergoing outpatient evaluation.</AbstractText>
          <CopyrightInformation>© 2020 American Academy of Neurology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Witek</LastName>
            <ForeName>Natalie</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Movement Disorders (NW, MA, DH), Rush University Medical Center, and Biostatistical Analysis (YL, BO), Department of Neurological Sciences, Rush University Medical Center, Chicago, IL.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Afshari</LastName>
            <ForeName>Mitra</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Movement Disorders (NW, MA, DH), Rush University Medical Center, and Biostatistical Analysis (YL, BO), Department of Neurological Sciences, Rush University Medical Center, Chicago, IL.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yuanqing</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Movement Disorders (NW, MA, DH), Rush University Medical Center, and Biostatistical Analysis (YL, BO), Department of Neurological Sciences, Rush University Medical Center, Chicago, IL.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ouyang</LastName>
            <ForeName>Bichun</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Movement Disorders (NW, MA, DH), Rush University Medical Center, and Biostatistical Analysis (YL, BO), Department of Neurological Sciences, Rush University Medical Center, Chicago, IL.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hall</LastName>
            <ForeName>Deborah</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Movement Disorders (NW, MA, DH), Rush University Medical Center, and Biostatistical Analysis (YL, BO), Department of Neurological Sciences, Rush University Medical Center, Chicago, IL.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neurol Clin Pract</MedlineTA>
        <NlmUniqueID>101577149</NlmUniqueID>
        <ISSNLinking>2163-0402</ISSNLinking>
      </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>25</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33968470</ArticleId>
        <ArticleId IdType="pmc">PMC8101295</ArticleId>
        <ArticleId IdType="doi">10.1212/CPJ.0000000000000854</ArticleId>
        <ArticleId IdType="pii">NEURCLINPRACT2019046052</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clinic Proc
2010;85:838–854.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2931619</ArticleId>
            <ArticleId IdType="pubmed">20810794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojas I, Graus F, Keime-Guibert F, et al. . Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology
2000;55:713–715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10980743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol
2008;7:327–340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2367117</ArticleId>
            <ArticleId IdType="pubmed">18339348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitoma H, Manto M, Hampe CS. Immune-mediated cerebellar ataxias: from bench to bedside. Cerebellum Ataxias
2017;4:16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5609024</ArticleId>
            <ArticleId IdType="pubmed">28944066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitoma H, Manto M, Hampe CS. Time Is Cerebellum. London: Cerebellum; 2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6028834</ArticleId>
            <ArticleId IdType="pubmed">29460203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nanri K, Okuma M, Sato S, et al. . Prevalence of autoantibodies and the efficacy of immunotherapy for autoimmune cerebellar ataxia. Intern Med
2016;55:449–454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26935362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones AL, Flanagan EP, Pittock SJ, et al. . Responses to and outcomes of treatment of autoimmune cerebellar ataxia in adults. JAMA Neurology
2015;72:1304–1312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26414229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurol
2002;1:294–305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12849427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blaes F, Strittmatter M, Merkelbach S, et al. . Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders. J Neurology
1999;246:299–303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10367699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Delattre JY, Antoine JC, et al. . Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry
2004;75:1135–1140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1739186</ArticleId>
            <ArticleId IdType="pubmed">15258215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zesiewicz TA, Wilmot G, Kuo SH, et al. . Comprehensive systematic review summary: treatment of cerebellar motor dysfunction and ataxia: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology
2018;90:464–471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5863491</ArticleId>
            <ArticleId IdType="pubmed">29440566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perlman S. Evaluation and Management of Ataxic Disorders: An Overview for Physicians. Minneapolis, MN: National Ataxia Foundation; 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>Samii A, Ryan-Dykes P, Tsukuda RA, Zink C, Franks R, Nichol WP. Telemedicine for delivery of health care in Parkinson's disease. J Telemed Telecare
2006;12:16–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16438773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keime-Guibert F, Graus F, Fleury A, et al. . Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry
2000;68:479–482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1736897</ArticleId>
            <ArticleId IdType="pubmed">10727484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saif MW, Tzannou I, Makrilia N, Syrigos K. Role and cost effectiveness of PET/CT in management of patients with cancer. Yale J Biol Med
2010;83:53–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2892773</ArticleId>
            <ArticleId IdType="pubmed">20589185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ebright MJ, Li SH, Reynolds E, et al. . Unintended consequences of Mayo paraneoplastic evaluations. Neurology
2018;91:e2057–e2066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6282240</ArticleId>
            <ArticleId IdType="pubmed">30366974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganesh A, Wesley SF. Practice current: when do you suspect autoimmune encephalitis and what is the role of antibody testing?
Neurol Clin Pract
2018;8:67–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5839684</ArticleId>
            <ArticleId IdType="pubmed">29517071</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
